TriangleNCT04241315 · CITED IN SOURCE DOCUMENTS
ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE3
- Status at capture
- COMPLETED
- Registry last update
- 2023-03-23
This is a phase 3, multi-center, single dose, open-label, exploratory study in suspected lung cancer patients scheduled to undergo endoscopic or thoracic surgery per CT/PET/MRI or other imaging based on standard of care. This study aims to assess the efficacy of OTL38 and Near Infrared Imaging (NIR) at identifying pulmonary nodules within the operating theater, and to assess the safety and tolerability of single intravenous doses of OTL38.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
Clinically Significant Events (CSE)
Localization of Primary Nodule
Identification of Cancerous Synchronous Lesions
Positive Resection Margins
Sensitivity for Cancerous Primary Nodules and Synchronous Lesions in FAS Subjects
False Positive Rate for Cancerous Primary Nodules and Synchronous Lesions in FAS Subjects
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Inclusion Criteria: 1. Male and Female subjects 18 years of age and older 2. Have a primary diagnosis, or a high clinical suspicion, of cancer in the lung warranting surgery based on CT/PET or other imaging 3. Are scheduled to undergo surgical thoracoscopy for diagnostic wedge resection followed by anatomic lung resection 4. Female subjects of childbearing potential or less than 2 years postmenopausal agree to use an acceptable form of contraception from the time of signing informed consent until 30 days after study completion 5. Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and to return for the required assessments Exclusion Criteria: 1. Previous exposure to OTL38 2. Any medical condition that in the opinion of the investigators could potentially jeopardize the safety of the subject 3. History of anaphylactic reactions to folate, including synthetic folic acid (pteroylmonoglutamic acid) and contrast agents containing indocyanine green for near infrared imaging. Subjects with a medical history of 'idiopathic anaphylaxis' will require evaluation. 4. History of allergy to any of the components of OTL38, including folic acid 5. A positive serum pregnancy test at Screening or a positive urine pregnancy test on the day of surgery or day of admission for female subjects of childbearing potential 6. Clinically significant abnormalities on electrocardiogram (ECG) at screening. 7. Presence of any psychological, familial, sociological condition or geographical challenges potentially hampering compliance with the study protocol and follow-up schedule 8. Impaired renal function defined as eGFR\< 50 mL/min/1.73m2 9. Impaired liver function defined as values \> 3x the upper limit of normal (ULN) for alanine aminotransferase (ALT) or aspartate aminotransferase (AST), alkaline phosphatase (ALP), or \>2x ULN for total bilirubin except in subjects with Gilbert's syndrome. 10. Received an investigational agent in another investigational drug or vaccine trial within 30 days prior to the administration of study drug 11. Known sensitivity to fluorescent light
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- All patients in this arm will receive OTL38 for injection and undergo intraoperative imaging.
- intervention Names
- Drug: OTL38 for Injection
- Device: Near infrared camera imaging system
- label
- Near-Infrared Imaging group
- type
- EXPERIMENTAL
- description
- All patients in this arm will receive OTL38 for injection but will not receive intraoperative imaging.
- intervention Names
- Drug: OTL38 for Injection
- label
- No Imaging Group
- type
- OTHER
- interventions
- arm Group Labels
- Near-Infrared Imaging group
- No Imaging Group
- description
- Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL
- name
- OTL38 for Injection
- other Names
- CYTALUX™ (pafolacianine) injection
- type
- DRUG
- arm Group Labels
- Near-Infrared Imaging group
- description
- Near infrared camera imaging system
- name
- Near infrared camera imaging system
- type
- DEVICE
Study design
- allocation
- RANDOMIZED
- intervention Model
- PARALLEL
- masking Info
- masking
- NONE
- primary Purpose
- DIAGNOSTIC
Enrollment
- count
- 112
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- The primary efficacy endpoint is the proportion of patients who demonstrate at least one CSE as a result of utilizing OTL-38 and Near Infrared Imaging.
- measure
- Clinically Significant Events (CSE)
- time Frame
- 1 day
- description
- Proportion of FAS subjects with one or more primary NIR fluorescence positive lung nodules (cancerous or non-cancerous, excluding normal lung parenchyma) not detected under normal light and/or palpation
- measure
- Localization of Primary Nodule
- time Frame
- 1 day
- description
- The proportion of FAS subjects with one or more NIR fluorescence positive cancerous synchronous lesions not detected under normal light and/or palpation
- measure
- Identification of Cancerous Synchronous Lesions
- time Frame
- 1 day
- description
- The proportion of FAS subjects with the identification of a cancerous positive margin that fluoresces within (less than or equal to) 10 mm of the surgical resection staple line
- measure
- Positive Resection Margins
- time Frame
- 1 day
- secondary Outcomes
- description
- Sensitivity or True Positive Rate (TPR) for OTL38 used with fluorescent light in FAS subjects, defined as the proportion of fluorescent light positive primary nodules and synchronous lesions that are histologically confirmed to be cancer relative to the total number of primary nodules and synchronous lesions confirmed to be cancer.
- measure
- Sensitivity for Cancerous Primary Nodules and Synchronous Lesions in FAS Subjects
- time Frame
- 1 day
- description
- False Positive Rate (FPR) for OTL38 used with fluorescent light in FAS subjects, defined as the proportion of fluorescent light positive primary nodules and synchronous lesions that are histologically confirmed not to be cancer relative to the total number of fluorescent light positive primary nodules and synchronous lesions
- measure
- False Positive Rate for Cancerous Primary Nodules and Synchronous Lesions in FAS Subjects
- time Frame
- 1 day
Full study description
- brief Summary
- This is a phase 3, multi-center, single dose, open-label, exploratory study in suspected lung cancer patients scheduled to undergo endoscopic or thoracic surgery per CT/PET/MRI or other imaging based on standard of care. This study aims to assess the efficacy of OTL38 and Near Infrared Imaging (NIR) at identifying pulmonary nodules within the operating theater, and to assess the safety and tolerability of single intravenous doses of OTL38.
Source references
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-13eafbc9640866800e66
- requested nct id
- NCT04241315
- primary nct id
- NCT04241315
- source kind
- fda_spl_label
- source record id
- 4cc23694-63af-f9f1-e063-6394a90a4ce0
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- payload sha256
- 050dbea4014674d1732be95b3210d89c93167ba74e41767a3d80acf6bcdf8fef
- payload
- application numbers
- NDA214907
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-13eafbc9640866800e66
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT04241315
- occurrences
- context exact
- 14.2 Patients with Known or Suspected Cancer in the Lung The safety and efficacy of CYTALUX were evaluated in a randomized, multicenter, open-label study (NCT04241315). The study enrolled 140 patients scheduled to undergo thoracoscopic or open segmental or subsegmental resection for primary lung lesions that were either conf
- end
- 166
- exact text
- NCT04241315
- start
- 155
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00300.json
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- source json pointer
- /results/21/clinical_studies/2
- source kind
- fda_spl_label
- source record id
- 4cc23694-63af-f9f1-e063-6394a90a4ce0
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 595140d7c151b52237e6d0259c60b2a5fd9e6be2e0205e47c3d7717846be2cfe
- spl effective time
- 20260401
- spl set id
- d21952b9-7c4e-3a56-e053-2a95a90a0ab0
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-7c92453a9e63589c07a0
- requested nct id
- NCT04241315
- primary nct id
- NCT04241315
- source kind
- fda_spl_label
- source record id
- 4cc23694-63af-f9f1-e063-6394a90a4ce0
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- payload sha256
- 82af9f72e84ef769572620c8f326145d831447090be014dece887f7f867ee492
- payload
- application numbers
- NDA214907
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-7c92453a9e63589c07a0
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT04241315
- occurrences
- context exact
- ve). 14.2 Patients with Known or Suspected Cancer in the Lung The safety and efficacy of CYTALUX were evaluated in a randomized, multicenter, open-label study (NCT04241315). The study enrolled 140 patients scheduled to undergo thoracoscopic or open segmental or subsegmental resection for primary lung lesions that were either conf
- end
- 1807
- exact text
- NCT04241315
- start
- 1796
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00300.json
- source file sha256
- bbaf8e3e49a06d91fa717d034adb1798932735c99e42d8d769cf5f9eb31d345e
- source json pointer
- /results/21/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- 4cc23694-63af-f9f1-e063-6394a90a4ce0
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 6a333fabbfbfb94fdabf2838c33fc47b8fec2f3e6f47b507f5d76473f9437d83
- spl effective time
- 20260401
- spl set id
- d21952b9-7c4e-3a56-e053-2a95a90a0ab0
Preserved source evidence · Not medical advice